FDA speeds up assessment of Sobi-Sanofi hemophilia drug
Another special designation from the US health authority will cut case processing time for drug candidate efanesoctocog alfa, a potential hemophilia A treatment.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
The US Food and Drug Administration (FDA) has opened a shortcut for a new hemophilia A drug candidate, efanesoctocog alfa (BIVV001).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi lifts forecast as blockbuster eczema drug gains
For subscribers
